Quels traitements pour le futur ? = Future treatmentsPAWLOTSKY, Jean-Michel.Hépato-gastro (Montrouge). 2010, Vol 17, pp 51-60, issn 1253-7020, 10 p., SUP5Article

Telaprevir to Boceprevir Switch Highlights Lack of Cross-ReactivityCARLSON, Amanda; GREGORICH, Zachery; STRIKER, Rob et al.Clinical infectious diseases. 2013, Vol 56, Num 4, pp 552-554, issn 1058-4838, 3 p.Article

Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis CKLIBANOV, Olga M; VICKERY, Stephen B; OLIN, Jacqueline L et al.Pharmacotherapy. 2012, Vol 32, Num 2, pp 173-190, issn 0277-0008, 18 p.Article

Traitement de l'hépatite C chronique = Treatment of chronic hepatitis CFONTAINE, Hélène; SOGNI, Philippe; POL, Stanislas et al.Hépato-gastro (Montrouge). 2011, Vol 18, Num 5, pp 461-469, issn 1253-7020, 9 p.Conference Paper

Review and Management of Drug Interactions With Boceprevir and TelaprevirKISER, Jennifer J; BURTON, James R; ANDERSON, Peter L et al.Hepatology (Baltimore, Md.). 2012, Vol 55, Num 5, pp 1620-1628, issn 0270-9139, 9 p.Article

Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal FunctionTREITEL, Michelle; MARBURY, Thomas; PRESTON, Richard A et al.Clinical pharmacokinetics. 2012, Vol 51, Num 9, pp 619-628, issn 0312-5963, 10 p.Article

Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?PASCALE, Alina; SERFATY, Lawrence.Journal of hepatology. 2013, Vol 58, Num 2, pp 391-394, issn 0168-8278, 4 p.Article

Les nouveaux traitements de l'hépatite C = New treatments for hepatitis C virus infectionSOGNI, P.Images en dermatologie. 2012, Vol 5, Num 1, pp 27-29, issn 1964-4167, 3 p.Article

Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative VolunteersHAMMOND, Kyle P; WOLFE, Pamela; BURTON, James R et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 1, pp 67-73, issn 1525-4135, 7 p.Article

Prise en charge des malades atteints d'hépatite chronique C de génotype 1 = Management of HCV genotype 1PAYEN, Jean-Louis; PERRIN, Hélène; DE LAVAISSIERE DE VERDUZAN, Marc et al.Hépato-gastro & oncologie digestive. 2012, Vol 19, Num 8, pp 668-681, issn 2115-3310, 14 p.Article

Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis CFOOTE, Bryce S; SPOONER, Linda M; BELLIVEAU, Paul P et al.The Annals of pharmacotherapy. 2011, Vol 45, Num 9, pp 1085-1093, issn 1060-0280, 9 p.Article

Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?PONS, Sarah Talavera; LAMBLIN, Geraldine; BOYER, Anne et al.European journal of clinical pharmacology. 2014, Vol 70, Num 7, pp 775-789, issn 0031-6970, 15 p.Article

Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysisPARK, C; JIANG, S; LAWSON, K. A et al.Journal of clinical pharmacy and therapeutics (Print). 2014, Vol 39, Num 1, pp 14-24, issn 0269-4727, 11 p.Article

Hépatite C: comment traiter le patient cirrhotique (naïf ou en échec de traitement) ? = Hepatitis C: how to treat cirrhotic patients, treatment-naïve or treatment-experienced?COSTENTIN, C; HEZODE, C.La Lettre de l'infectiologue. 2013, Vol 28, Num 6, pp 209-214, issn 0296-9009, 6 p.Article

Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis CCHANG, Mei H; GORDON, Lori A; FUNG, Horatio B et al.Clinical therapeutics. 2012, Vol 34, Num 10, pp 2021-2038, issn 0149-2918, 18 p.Article

Characterization of resistance mutations against HCV ketoamide protease inhibitorsXIAO TONG; BOGEN, Stephane; RALSTON, Robert et al.Antiviral research. 2008, Vol 77, Num 3, pp 177-185, issn 0166-3542, 9 p.Article

Actualités sur les nouveaux traitements de l'infection par le VHC: résultats des dernières études évaluant les antiprotéases et les antipolymérasesSOGNI, Philippe.La Lettre de l'hépato-gastroentérologue. 2011, Vol 14, Num 1, issn 1286-580X, 15 p., SUPSerial Issue

Hypersensibilité aux nouveaux traitements de l'hépatite C = Hypersensitivity to new therapy for hepatitis C infectionMILPIED-HOMSI, B; VALEYRIEM-ALLANORE, L; DUPIN, N et al.Revue française d'allergologie (Amsterdam. Print). 2013, Vol 53, Num 3, pp 171-173, issn 1877-0312, 3 p.Article

NS5A inhibitors: A new breakthrough for the treatment of chronic hepatitis CASSELAH, Tarik.Journal of hepatology. 2011, Vol 54, Num 5, pp 1069-1072, issn 0168-8278, 4 p.Article

Bocéprévir: atteintes hématologiques gravesLa Revue Prescrire. 2014, Vol 34, Num 367, issn 0247-7750, p. 350Article

Characterization of Resistance to the Protease Inhibitor Boceprevir in Hepatitis C Virus-Infected PatientsSUSSER, Simone; WELSCH, Christoph; ZEUZEM, Stefan et al.Hepatology (Baltimore, Md.). 2009, Vol 50, Num 6, pp 1709-1718, issn 0270-9139, 10 p.Article

Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and TelaprevirAOURI, Manel; MORADPOUR, Darius; CAVASSINI, Matthias et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 7, pp 3147-3158, issn 0066-4804, 12 p.Article

Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naïve Infected IndividualsFONSECA-CORONADO, Salvador; ESCOBAR-GUTIERREZ, Alejandro; RUIZ-TOVAR, Karina et al.Journal of clinical microbiology (Print). 2012, Vol 50, Num 2, pp 281-287, issn 0095-1137, 7 p.Article

Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionBACON, Bruce R; GORDON, Stuart C; BURROUGHS, Margaret et al.The New England journal of medicine. 2011, Vol 364, Num 13, pp 1207-1217, issn 0028-4793, 11 p.Article

Page / 4